The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy
Open accessAbstract
Background—: Chemically measured high-density lipoprotein cholesterol (HDL-C) may not be the best clinical measure of HDL. Little is known about alternative HDL measures such as HDL size or particle number (HDL-P) as determinants of residual risk after potent statin therapy. Methods and Results—: In Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), HDL size and HDL-P were measured by nuclear magnetic resonance spectroscopy, and HDL-C and apolipoprotein A-I (apoA-I) were chemically assayed in 10 886 participants without cardiovascular disease (CVD) before and after random allocation to rosuvastatin 20 mg/d or placebo. Levels were examined with first CVD (n=234). HDL-P correlated better with apoA-I (Spearman r =0.69, P <0.0001) than with HDL-C ( r =0.55, P <0.0001). Rosuvastatin lowered low-density lipoprotein cholesterol (49%) and raised HDL-C (6.1%), apoA-I (2.1%), HDL-P (3.8%), and HDL size (1.2%); all P <0.0001. Among placebo-allocated individuals, on-treatment HDL-C, apoA-I, and HDL-P had similar inverse associations with CVD (risk factor–adjusted hazard ratio and 95% confidence interval per 1 standard deviation: 0.79 [0.63–0.98], 0.75 [0.62–0.92], and 0.81 [0.67–0.97], respectively). Among rosuvastatin-allocated individuals, on-treatment HDL-P had a statistically significant and somewhat stronger association with CVD (0.73, 0.57–0.93, P =0.01) than HDL-C (0.82, 0.63–1.08, P =0.16) or apoA-I (0.86, 0.67–1.10, P =0.22). Among rosuvastatin-allocated individuals, on-treatment HDL-P remained significant (0.72, 0.53–0.97, P =0.03) after additionally adjusting for HDL-C. In risk factor–adjusted models, HDL size showed no significant association with CVD. Conclusions—: In the setting of potent statin therapy, HDL particle number may be a better marker of residual risk than chemically measured HDL-C or apoA-I. This has potential implications for evaluating novel therapies targeting HDL. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00239681.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022 · cited 1×
“Finally, in the recent dal-OUTCOMES trial where dalcetrapib was given on a background of statin treatment, baseline HDL-C did not predict risk, although HDL-P and HDL size were not evaluated.(5) Strengths of this study include the large number of individuals with HDL measures assessed both at baseline and on-treatment…”
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943 · cited 2×
“Because HDL particles are quite heterogeneous, and because their functions cannot be inferred from the plasma concentration of chemically measured HDL-C, interest has focused recently on measuring HDL-P, HDL size, and various HDL functions.(14,20) HDL-C is correlated with other HDL parameters such as size and HDL-P, b…”
Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
Cited by
HDL and cardiovascular disease
Rader, D. J., & Hovingh, G. K. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61217-4 · Cited by 870
Impact of Obesity and Metabolic Syndrome on Immunity
Andersen, C. J., Murphy, K. E., & Fernandez, M. L. (2016) · Advances in Nutrition · doi:10.3945/an.115.010207 · Cited by 701
Würtz, P., Kangas, A. J., Soininen, P., Lawlor, D. A., Davey Smith, G., & Ala-Korpela, M. (2017) · American Journal of Epidemiology · doi:10.1093/aje/kwx016 · Cited by 686
HDL-targeted therapies: progress, failures and future
Kingwell, B. A., Chapman, M. J., Kontush, A., & Miller, N. E. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4279 · Cited by 354
LDL cholesterol: controversies and future therapeutic directions
Ridker, P. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61009-6 · Cited by 274
Self-citationTardif, J.-C., Ballantyne, C. M., Barter, P., Dasseux, J.-L., Fayad, Z. A., Guertin, M.-C., Kastelein, J. J. P., Keyserling, C., Klepp, H., Koenig, W., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu171 · Cited by 251
Mora, S., Caulfield, M. P., Wohlgemuth, J., Chen, Z., Superko, H. R., Rowland, C. M., Glynn, R. J., Ridker, P. M., & Krauss, R. M. (2015) · Circulation · doi:10.1161/circulationaha.115.016857 · Cited by 126
“This also contrasts with our prior finding in JUPITER that HDL-p as measured by nuclear magnetic resonance was inversely associated with CVD among both the placebo- and rosuvastatin-allocated arms.(32) This could relate to differences in the lipoprotein isolation method for the IM method that were Figure 2.”
ResultSelf-citationHagström, E., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Danchin, N., Diaz, R., Goodman, S. G., Harrington, R. A., Jukema, J. W., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.057807 · Cited by 118
Pedersen, L. R., Olsen, R. H., Anholm, C., Astrup, A., Eugen-Olsen, J., Fenger, M., Simonsen, L., Walzem, R. L., Haugaard, S. B., & Prescott, E. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0934-x · Cited by 98
Fernández‐Castillejo, S., Valls, R., Castañer, O., Rubió, L., Catalán, Ú., Pedret, A., Macià, A., Sampson, M. L., Covas, M., Fitó, M., et al. (2016) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201501068 · Cited by 61
“Keywords: HDL-C/HDL-P and LDL-P/HDL-P ratios / Lipoprotein subclasses / Olive oil / Polyphenols / Thyme Additional supporting information may be found in the online version of this article atthe publisher’s web-site Correspondence: Rosa Solà E-mail: rosa.sola@urv.cat Abbreviations: CHD, coronary heart disease; HDL-C,…”
Andrews, J., Janssan, A., Nguyen, T., Pisaniello, A. D., Scherer, D. J., Kastelein, J. J. P., Merkely, B., Nissen, S. E., Ray, K., Schwartz, G. G., et al. (2017) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2017.01.01 · Cited by 53
Update on the laboratory investigation of dyslipidemias
Ramasamy, I. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.01.015 · Cited by 50
von Eckardstein, A., & Rohrer, L. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000294 · Cited by 33
Koyama, S., Horie, T., Nishino, T., Baba, O., Sowa, N., Miyasaka, Y., Kuwabara, Y., Nakao, T., Nishiga, M., Nishi, H., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012609 · Cited by 23
Metadata
- Authors
- Mora, S., Glynn, R. J., & Ridker, P. M.
- Venue
- Circulation
- Published
- 2013-09-10
- Volume
- 128
- Issue
- 11
- Pages
- 1189-1197
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2128361838
- Cited by
- 237
- References
- 14
- FWCI
- 26.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.